• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• TIL Therapy Development
  • One-Stop TIL Development
  • Special TIL Therapy Development
• CIK Therapy Development
  • One-Stop CIK Therapy Development
  • CIK Therapy Improvement
• Artificial T Cell-Stimulating Platform Development
  • Artificial T Cell Stimulator Development
  • Hydrogel-based Artificial T Cell-Stimulating Platform Development
  • DNA-based Artificial T Cell-Stimulating Platform Development
  • Alternative Polymeric-based Artificial T Cell-Stimulating Platform Development
  • Soluble Artificial T Cell-Stimulating Platform Development
  • Artificial T Cell-Stimulating System Function Characterization
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Sleeping Beauty Transposon System for CAR-T

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs has been a world-famous scientific partner in the field of antibody discovery and cell-based immunotherapy for years. Now, our scientists are proud to offer advanced Sleeping Beauty (SB) transposon system as an important non-virial transfection system for CAR-T gene delivery.

Background

Viral vectors play important roles in traditional CAR-T cell therapy nowadays. Although they are promising, imitations still exist. Firstly, using viral vector carries a risk of insertional oncogenesis or clonal dominance. Meanwhile, when administered directly in vivo, viral vectors may cause unwanted immunogenicity. Moreover, it is cumbersome and costly for the manufacturing of viral vector since living cells are required and the quality control is complicated as well as the downstream processing. Therefore, we bring out the SB transposon system as an alternative of viral vectors to circumvent some of these limitations.

Introduction of SB Transposon System

SB transposon system is a wonderful synthetic DNA transposon which is composed of two components, a transposase (360 amino acids) and a transposon. It is designed to precisely integrate defined DNA sequences into a TA dinucleotide of vertebrate animals. It is a simple, cut-and-paste manner to translocate DNA from one site to another. As shown in Fig 1, plasmid 1 is loaded with a transgene (the CAR gene), named transposon, surrounded by inverted repeats (IRs) that contain short direct repeats (DRs). Plasmid 2 encodes the enzyme (transposase) which can recognize the sequences from plasmid 1 and cut the transposon out of the plasmid 1. Then the CAR gene will be successfully delivered into the targeted cell (T cell) cytoplasm and inserted randomly into TA dinucleotide base pairs of the recipient DNA sequence. By this means, stable integration and reliable long-term expression of the CAR genes in T cells is possible and attractive.

Fig 1. Schema of the transposon/transposase SB system.¹

Highlight Features of Our System and Our Service

• This system is composed solely of DNA resulting in cheaper costs of production and delivery compared with viral vectors.
• Large cargo capacity up to 12 kb.
• Minimal immunogenicity in vivo and well incorporated with our CAR platforms.
• Higher transposition activity in mammalian cells compared with some other transposon systems.
• Ph.D. level scientists work closely with each other to guarantee the highest success rate of every project.
• Firm quality control of every step to ensure reliable quality

Empowered by high-end technologies and platforms, Creative Biolabs has served numerous customers from research institution and pharmacology industry. We are more than happy to share our experience, platforms, and resources with you to promote each project closer to clinical trials. Please don't hesitate to contact us for more details and our team will get back to you as soon as possible.

Reference

1. Heiblig M, et.al. (2015). Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells. 7(7), 1022-38.